By Elric Langton | 13 June 2022
Elric and Mike have a financial interest in SkinBioTherapeutics
I have a financial interesting SkinBioTherapeutics.
I have had a bit of a catchup with the CEO of SkinBioTherapeutics Plc (SBTX), Stuart Ashman. He was gracious and generous with his time, which is greatly appreciated because I know he is snowed under with a lot of work.
On the surface, it would be an easy mistake to assume the team at SkinBioTherapeutics cannot be too busy because it only has two commercial agreements, and the first to market, AxisBiotix Ps, is not doing so well. The second, Croda Plc (CRDA), has not yet launched a product, SkinBioTherapeutics lysate, so what is the board doing? This assumption, along with another, such as AxisBiotix Ps, has wholly flopped, and so has the Company. This is a preposterous notion, born out of frustration of a declining share price from 75p October 2021 to today’s 18.50p BIDp. This completely ignores the wider market, and I mean a much broader market, be it small, mid or large capitalised shares. The macro market is not good. So, to look at any Company in isolation is foolhardy.
The Company pushed out an RNS late afternoon, but before this, I teased a few peeps with a “selfless promotional” comment being “inbound”, which was enough to improve on the 19% daily drop to 12%. However, I will be disappointed if this is not improved in the following days and weeks. Why? Because I had a productive and encouraging chat with CEO Stuart Ashman and the new CFO, Manprit Randhawa.
Today’s chat with Stuart and Manprit was one point not covered: the sale order numbers. I have previously mentioned order numbers and the conspiracy surrounding the sequence. It is randomised, irrelevant, and updated to give us a more significant data dive for analysis as we grow and learn. They are random. They ping between a set of brackets and are changing very soon. They have changed twice already. They are region-specific and have regions within regions. It’s not as complex as it sounds, but people are paying too much attention. They’re on a wild goose chase.
Topics Covered
Aborting of £1.2 million AxisBiotix Ps probiotic target
AxisBiotix Ps sales momentum & Improved retention rates from 70% to 80% or more
Marketing strategy - including the use of influencers and the national press
Improved margins despite additional staff
Oral Care
Croda & Sederma
Opinions
We offer no advice or solicit the purchase of any of the shares in any companies we discuss. However, share does go up and down in value; therefore, your financial situation is a risk.
The views and opinions contained within these editorials are for research purposes and are opinions of the author(s). We aim to be accurate as possible but stress you should also perform your own research and never act solely on the contents of these editorials.
SkinBioTherapeutics Plc